Researchers provided genetic diagnoses for about 68 percent of their primary antibody deficiency cohort, which altered clinical management in about half of them.
The study found that resistant clones in triple-negative breast tumors existed prior to chemo, but transcriptional changes happened in response to therapy.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
Investigators intend to genotype the biorepository using Illumina arrays with the aim of identifying markers that can be used to inform treatment and prevention efforts.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
The researchers reported single-cell small-RNA profiling could have applications in studying tumor heterogeneity as well as for in vitro fertilization.
The researchers will use single-cell genomics and other approaches to generate information that could ultimately be used to diagnose, monitor, and treat disease.
